



Highest-Ever EBITDA Margins

Est. Vs. Actual for Q2FY25: Revenue—**INLINE**; EBITDA Margin—**BEAT**; PAT— **BEAT**.

Changes in Estimates post Q2FY25

FY25E/FY26E: Revenue: 2%/2.3%; **EBITDA Abs.:** 4.4%/4.3%; **PAT:** 4.2%/4.1%

Recommendation Rationale

- AIL reported revenue growth of 9.3% YoY in Q2FY25, slightly ahead of expectations of 8% YoY. Abbott's growth of 9.3% outpaced the IPM's growth of 8.0%.
- An increase in secondary sales and a higher share of Cremaffin, Udiliv, and Rybelsus, which reported QoQ growth of 28%, 20.2%, and 34.7% respectively, contributed to the improved market share.
- The company reported EBITDA margins of 26.9%, up 139bps YoY and 178bps QoQ, primarily due to lower Opex.

Sector Outlook: Positive

Company Outlook & Guidance: Abbott India is growing 1.2x to 1.5x faster than IPM, driven by high brand recognition and an excellent product portfolio.

Current Valuation: PE 40x for 1HFY27E Earnings (Earlier Valuation: PE 44x FY26)

Current TP: Rs 31,420/share (Earlier TP: Rs 31,000/share)

Recommendation: BUY

Financial Performance

AIL reported revenue growth of 9.3% YoY, surpassing the IPM's growth of 8.0% in Q2FY25. While Chronic growth halved to 8%, the Acute therapy segment registered a 7.3% growth. The company achieved higher sales growth due to a change in product mix and new product launches, as well as a higher share of Cremaffin, Udiliv, and Rybelsus, which reported QoQ growth of 28%, 20.2%, and 34.7% respectively, resulting in improved market share capture. However, this was partially offset by Mixtard and Novomix, which recorded 8.4% growth and 7.9% de-growth, leading to high single-digit topline growth.

Growth in other key therapies, such as Cardiac (+14.1% QoQ) and Gastro (+14.6% QoQ), was above IPM growth. The company's 35% Anti-diabetic segment grew by 5%, while the rest of the portfolio grew by around 13%, outpacing IPM.

The company's gross margins improved by 178bps QoQ, attributed to changes in product mix with a higher share of Cremaffin and Vitamins. EBITDA margins stood at 25.1%, up 202bps QoQ, driven by enhanced gross profits and a reduction in other expenses. The company also reported PAT of Rs 359 Cr, marking a 14.3% QoQ growth, driven by high operating profitability.

Key Financials (Consolidated)

(Rs Cr)	Q2FY25	QoQ (%)	YoY (%)	Axis Est.	Variance %
Net Sales	1,633	4.8%	9.3%	1,614	1.2%
EBITDA	439	12.3%	23.6%	402	9.2%
EBITDA Margin	26.9%	178	139	24.9%	-
Net Profit	359	9.3%	14.6%	337	6.6%
EPS (Rs)	168.8	9.3%	14.6%	158.4	6.6%

Source: Company, Axis Securities Research

(CMP as of 07th November 2024)

CMP (Rs)	28,180
Upside /Downside (%)	12%
High/Low (Rs)	30,521/22,000
Market cap (Cr)	59,800
Avg. daily vol. (6m) Shrs	10,000
No. of shares (Cr)	2.12

Shareholding (%)

	Mar-24	Jun-24	Sep-24
Promoter	75.0	75.0	75.0
FII's	0.2	0.2	0.2
MFs / UTI	7.6	7.6	7.7
Banks	0.0	0.0	0.0
Others	17.2	17.2	17.2


Financial & Valuations

Y/E Mar (Rs Cr)	FY24	FY25E	FY26E
Net Sales	5,849	6,646	7,403
EBITDA	1,453	1,701	1,910
Net Profit	1,201	1,349	1,499
EPS (Rs)	565.3	635.0	705.3
PER (x)	49.8	44.4	40.0
P/BV (x)	39.8	33.7	29.6
EV/EBITDA (x)	16.2	13.7	11.6
ROE (%)	32.5	31.0	29.0

Change in Estimates (%)

Y/E Mar	FY25E	FY26E
Sales	2.0%	2.3%
EBITDA	4.4%	4.3%
PAT	4.2%	4.1%

Relative performance:



Source: Ace Equity

Ankush Mahajan
Research Analyst
Email: ankush.mahajan@axissecurities.in

Aman Goyal
Research Associate
Email: aman.goyal@axissecurities.in

Outlook

Abbott India's 'Beyond the Pill' strategy, which encompasses consumer education, diagnosis, treatment, and compliance, is expected to drive continued growth. The company is growing 1.2 to 1.5 times faster than the IPM, driven by its strong brand recognition and excellent product portfolio.

Valuation & Recommendation

Based on Abbott India's ability to outpace the IPM and leverage its better product mix with new launches, we maintain a BUY rating on the stock. We have set a target price of Rs 31,420/share, which implies an upside potential of 12% from the CMP. This valuation is based on a multiple of 40x PE for H1FY27E.

Key Highlights

AIOCD Data for Q2FY25: In Q2FY25, Abbott India reported a revenue growth of 9.3% YoY, outpacing the IPM industry growth of 8%. Key therapies such as Cremaffin, Udiliv, and Rybelsus experienced robust growth, with QoQ increases of 28%, 20.2%, and 34.7%, respectively. Other notable therapies like RYZODEG and Duphalac grew by 22% and 12.8%, respectively, while the CNS and Vertin segments saw declines of 1.8% and 4%, respectively.

Abbott India's key gynaecological therapy, Duphaston, witnessed a QoQ degrowth of 6% in Q2FY25, owing to competition from Mankind's "Dydrogesterone." However, stable sales of Duphaston and increased volumes of the Thyronorm and Rybelsus brands are expected to drive Abbott India's growth. We anticipate the company will achieve a Revenue and PAT CAGR of 12% and 11%, respectively, over FY24-FY27E.

Healthy cash flow generation strengthening balance sheet

So far in H1FY25, Abbott India Ltd. (AIL) generated a robust cash flow of Rs 676 Cr, elevating its cash reserves to Rs 1,100 Cr by the end of H1FY25. The company's branded business is anticipated to enhance overall profitability. With a strong Free Cash Flow to Firm (FCFF) to EBITDA ratio of 65%, along with high return ratios and substantial dividend payouts, AIL is well-positioned for continued financial stability and growth.

Key Risks to Our Estimates and TP

- The launch of similar molecules in the same therapies may impact revenue growth
- Entry of more products into NELM may impact its profitability.
- An increase in Royalty to parents may impact the company's profitability.

Change in Estimates

	New		Old		Change (%)	
	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Sales	6,646	7,403	6,515	7,236	2.0%	2.3%
EBITDA	1,701	1,910	1,629	1,831	4.4%	4.3%
PAT	1,349	1,499	1,295	1,440	4.2%	4.1%

Source: Company, Axis Securities Research

Results Review

Particulars (Rs Cr)	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	YoY (%)	QoQ (%)
Net Sales	1,494	1,437	1,439	1,558	1,633	9.3	4.8
Growth (%)	8.3%	8.3%	7.1%	5.3%	9.3%		
Total Expenditure	1,113	1,049	1,109	1,167	1,194	7.2	2.3
Raw Material Consumed	140	117	162	146	172		
Stock Adjustment	640	668	747	781	738		
Development Costs	34	-8	-103	-81	-9		
% of sales	54.5%	54.1%	56.0%	54.3%	55.2%		
Gross Margins (%)	45.5%	45.9%	44.0%	45.7%	44.8%	-7.3	-9.0
Employee Expenses	143	139	145	161	147	3.3	-8.5
% of sales	9.6%	9.7%	10.1%	10.3%	9.0%		
Other Expenses	156	133	158	159	145	-7.5	-9.2
% of sales	10.5%	9.3%	11.0%	10.2%	8.9%		
EBITDA	381	388	330	391	439	23.6	12.3
EBITDAM (%)	25.5%	27.0%	22.9%	25.1%	26.9%	139	178
Interest	3	3	3	3	3		
Depreciation	18	18	18	18	18		
Other Income	56	56	81	67	60		
PBT	415	422	390	437	479	15.4	9.7
Tax	102	111	103	109	121		
Tax (%)	24.7%	26.3%	26.3%	25.0%	25.2%		
Reported PAT	313	311	287	328	359	14.6	9.3

Source: Company, Axis Securities Research

Therapy wise breakup

Drug	Therapy	Value (Rs Cr)	YoY (%)
Thyronorm	Hormones	630	5.4%
Duphaston	Gynaecological	387	4.2%
Udiliv	Gastrointestinal	608	25.2%
Vertin	Neuro / CNS	292	0.3%
Duphalac	Gastrointestinal	323	7.1%

Source: IPM

Financials (Consolidated)

Profit & Loss

(Rs Cr)

Particulars (Rs Cr)	FY24	FY25E	FY26E	FY27E
Net Sales	5,849	6,646	7,403	8,130
Growth (%)	9.4%	13.6%	11.4%	9.8%
Total Expenditure	4,396	4,944	5,493	6,024
Raw Material Consumed	3,221	3,635	4,034	4,423
Gross margins (%)	44.9%	45.3%	45.5%	45.6%
Employee Expenses	577	658	733	805
% of sales	9.9%	9.9%	9.9%	9.9%
Other Expenses	599	651	725	797
% of sales	10.2%	9.8%	9.8%	9.8%
EBIDTA	1,453	1,701	1,910	2,106
EBITDAM (%)	24.8%	25.6%	25.8%	25.9%
Depreciation	71	84	100	116
EBIT	1,382	1,617	1,810	1,990
EBITM (%)	23.6%	24.3%	24.4%	24.5%
Interest	12	12	12	12
Other Income	248	206	214	216
PBT	1,618	1,811	2,012	2,194
Tax Rate (%)	25.7%	25.5%	25.5%	25.5%
Tax	417	462	513	559
Reported PAT	1,201	1,349	1,499	1,634

Source: Company, Axis Securities Research

Balance Sheet

(Rs Cr)

Y/E Mar, Rs. Cr	FY24	FY25E	FY26E	FY27E
Share Capital	21.3	21.3	21.3	21.3
Reserves & Surplus	3,678	4,336	5,145	6,088
Shareholders Fund	3,699	4,358	5,166	6,110
Total Loan	83	83	83	83
Trade Payables	1,003	1,147	1,278	1,403
Provisions	252	262	272	282
Other Liabilities	157	177	197	217
Total Liabilities	5,193	6,026	6,995	8,095
Gross Block	340	420	500	580
Depreciation	193	277	377	493
% of GB	56.7%	65.9%	75.3%	84.9%
Net Block	147	143	123	87
Fixed Assets	235	231	211	175
Deferred Tax Asset(Net)	0	0	0	0
Long-Term Loans & Advances	0	0	0	0
Other Non-Current Assets	1,713	1,821	2,028	2,227
Inventories	620	728	811	891
Trade Receivables	319	364	406	445
Cash & Cash Equivalents	2,134	2,700	3,347	4,153
Loans & Advances	0	0	0	0
Other Assets & Liabilities	1,885	2,003	2,221	2,430
Total Assets	5,193	6,026	6,995	8,095

Source: Company, Axis Securities Research

Cash Flow

(Rs Cr)

Y/E Mar, Rs Cr	FY24	FY25E	FY26E	FY27E
PBT	1,618	1,811	2,012	2,194
Add: Depreciation	71	84	100	116
Add: Interest	12	12	12	12
Cash flow from operations	1,701	1,907	2,124	2,322
Change in working capital	306	97	181	173
Taxes	417	462	513	559
Net cash from operations	979	1,348	1,430	1,589
Capital expenditure	-95	-80	-80	-80
Net cash from investing	-95	-80	-80	-80
Increase/Decrease in debt	-30	0	0	0
Dividends	-691	-691	-691	-691
Proceedings from equity	0	0	0	0
Others	46	-0	-0	0
Net cash from financing	-687	-703	-703	-703
Net Inc./ (Dec.) in Cash	197	565	647	806
Opening cash balance	1,937	2,134	2,700	3,347
Closing cash balance	2,134	2,700	3,347	4,153

Source: Company, Axis Securities Research


Ratio Analysis

(%)

Y/E March	FY24	FY25E	FY26E	FY27E
Operational Ratios				
Sales growth (% YoY)	9.4	13.6	11.4	9.8
EBITDA growth (% YoY)	20.5	17.1	12.3	10.3
Net Profit growth (% YoY)	26.5	12.3	11.1	9.0
EBITDA Margin %	24.8	25.6	25.8	25.9
Net profit Margin %	20.5	20.3	20.2	20.1
Tax Rate %	25.7	25.5	25.5	25.5
Efficiency Ratios				
Total Asset Turnover (x)	1.1	1.1	1.1	1.0
Sales/Gross block (x)	17.2	15.8	14.8	14.0
Sales/Net block(x)	39.7	46.4	60.1	93.2
Working capital/Sales (x)	-0.01	-0.01	-0.01	-0.01
Valuation Ratios				
PER (x)	49.8	44.4	40.0	36.6
P/BV (x)	16.2	13.7	11.6	9.8
EV/Ebitda (x)	39.8	33.7	29.6	26.5
EV/Sales (x)	9.9	8.6	7.6	6.9
Dividend Yield (%)	1.2	1.2	1.2	1.2
Return Ratios				
ROE	32.5	31.0	29.0	26.7
ROIC	45.2	48.6	49.6	50.5

Source: Company, Axis Securities Research

Abbott India Price Chart and Recommendation History



Date	Reco	TP	Research
15-Feb-23	BUY	23,000	Result Update
22-May-23	HOLD	22,000	Result Update
11-Aug-23	HOLD	25,000	Result Update
13-Nov-23	HOLD	25,000	Result Update
02-Feb-24	BUY	28,400	Result Update
10-May-24	BUY	28,000	Result Update
08-Aug-24	BUY	31,000	Result Update
08-Nov-24	BUY	31,420	Result Update

Source: Axis Securities Research

DISCLAIMER:

Axis Securities Limited is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector banks and has various subsidiaries engaged in businesses of Asset Management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.

Axis Securities Limited, is registered as a

- Stock Broker, Depository Participant, Portfolio Manager, Investment Adviser and Research Analyst with Securities and Exchange Board of India
- Corporate Agent with Insurance Regulatory and Development Authority of India
- Point of Presence with Pension Fund Regulatory and Development Authority
- Distributor for Mutual Funds with AMFI

Registration Details:

SEBI Single Reg. No.- NSE, BSE, MSEI, MCX & NCDEX – INZ000161633 | SEBI Depository Participant Reg. No. IN-DP-403-2019 | Portfolio Manager Reg. No.- INP000000654 | Investment Advisor Reg No. INA000000615 | SEBI-Research Analyst Reg. No. INH000000297 | IRDA Corporate Agent (Composite) Reg. No. CA0073| PFRDA – POP Reg. No. POP387122023 | Mutual Fund Distributor ARN- 64610.

Compliance Officer Details: Name – Mr. Maneesh Mathew, Tel No. – 022-68555574, Email id – compliance.officer@axisdirect.in;

Registered Office Address – Axis Securities Limited, Unit No.002, Building- A, Agastya Corporate Park, Piramal Realty, Kamani Junction, Kurla (W), Mumbai – 400070.

Administrative office address: Axis Securities Limited, Aurum Q Parc, Q2 Building, Unit No. 1001, 10th Floor, Level – 6, Plot No. 4/1 TTC, Thane – Belapur Road, Ghansoli, Navi Mumbai, Pin Code – 400710.

In case of any grievances please call us at 022-40508080 or write to us helpdesk@axisdirect.in.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in last five years. However, SEBI, Exchanges, Clearing Corporations and Depositories etc. have conducted the routine inspection and based on their observations have issued advise/warning/show cause notices/deficiency letters/ or levied penalty or imposed charges for certain deviations observed in inspections or in normal course of business, as a Stock Broker / Depository Participant/Portfolio Manager. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

By referring to any particular sector, Axis Securities does not provide any promise or assurance of favourable view for a particular industry or sector or business group in any manner.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors. Our research should not be considered as an advertisement or advice, professional or otherwise. This research report and its respective content by Axis Securities made available on this page or otherwise do not constitute an offer to sell or purchase or subscribe for any securities or solicitation of any investments or investment services for the residents of Canada and / or USA or any jurisdiction where such an offer or solicitation would be illegal.

Subject company(ies) may have been client during twelve months preceding the date of distribution of the research report. Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment of its original date of publication by ASL and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments.

The information and opinions in this report have been prepared by Axis Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Axis Securities. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite, investment objective or the particular circumstances of an individual investor. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and the like and take professional advice before investing.

While we would endeavour to update the information herein on a reasonable basis, Axis Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Axis Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Axis Securities policies, in circumstances where Axis Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained in good faith from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Axis Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Axis Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Axis Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. Axis Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction. Axis Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months. Axis Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. Axis Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Axis Securities nor Research Analysts and / or their relatives have any material conflict of interest at the time of publication of this report. Please note that Axis Securities has a

proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Research Analyst may have served as an officer, director or employee of subject company(ies). Axis Securities or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. Since associates of Axis Securities and Axis Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report. Axis Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Certain transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

We and our affiliates/associates, officers, directors, and employees, Research Analyst(including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of Research Report or at the time of public appearance. Axis Securities may have proprietary long/short position in the above mentioned scrip(s) and therefore may be considered as interested. This should not be construed as invitation or solicitation to do business with Axis Securities. Axis Securities is also a Portfolio Manager. Portfolio Management Team (PMS) takes its investment decisions independent of the PCG research and accordingly PMS may have positions contrary to the PCG research recommendation.

RATING SCALE: Definitions of ratings

Ratings	Expected absolute returns over 12 – 18 months
BUY	More than 10%
HOLD	Between 10% and -10%
SELL	Less than -10%
NOT RATED	We have forward looking estimates for the stock, but we refrain from assigning valuation and recommendation.
UNDER REVIEW	We will revisit our recommendation, valuation and estimates on the stock following recent events
NO STANCE	We do not have any forward-looking estimates, valuation or recommendation for the stock

Note: Returns stated in the rating scale are our internal benchmark.